Four Cases of Single-Fraction Stereotactic Body Radiation Therapy for Prostate Cancer

Hypofractionated radiotherapy for prostate cancer has been reported to date. Here, we report on four patients with prostate cancer who were treated with single-fraction stereotactic body radiation therapy. It was conducted with reference to some previous clinical trials. The median age of the patients was 76.5 years (range: 72-89 years). All except one patient with low-risk prostate cancer received androgen deprivation therapy (ADT) before irradiation. All patients received a dose of 24 Gy in one fraction using X-ray photon beams when prostate-specific antigen (PSA) fell to low levels due to ADT. After irradiation, all patients had a gradual decline in PSA, and so far none has had a PSA recurrence. Although Grade 1-2 adverse events occurred in all cases, none of the patients showed adverse events of Grade 3 or over during the observation period.